Abstracts tagged "meta-analysis and psoriatic arthritis"

Abstract Number: 696 • ACR/ARHP Annual Meeting 2018
Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
Chenyang Lu^1,2, Beth Wallace^3,4,5, Wenyi Fu^2,6 and Yi Liu¹, ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ²Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ⁵Institute for Healthcare Policy and Innovation, Michigan Medicine, Ann Arbor, MI, ⁶Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, Shenyang, China
Background/Purpose: Many targeted synthetic DMARD (tsDMARD) and biological DMARD (bDMARD) were recently approved for treatment of active psoriatic arthritis (PsA), but their comparative efficacy and…
Abstract Number: 701 • ACR/ARHP Annual Meeting 2018
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Vibeke Strand¹, M. Elaine Husni², Jenny Griffith³, Yan Song⁴, Rakesh Singh⁵, Jing Zhao⁶ and Keith A. Betts⁷, ¹Stanford University, Palo Alto, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Analysis Group Inc, Boston, MA, ⁷Analysis Group, Inc., Los Angeles, CA
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
Abstract Number: 1651 • ACR/ARHP Annual Meeting 2018
Epidemiology of Depression and Anxiety in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Enav Z. Zusman^1,2,3, Alyssa Howren^1,2,3, Jan Dutz⁴ and Mary A. De Vera^1,2,3, ¹Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Shared inflammatory processes underscore a substantial burden and risk of psychiatric complications – namely depression and anxiety – in patients with psoriatic arthritis (PsA),…
Abstract Number: 2564 • ACR/ARHP Annual Meeting 2018
Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients
Alice B Gottlieb¹, Philip J. Mease², Bruce Kirkham³, Peter Nash⁴, Alejandro Balsa⁵, Bernard Combe⁶, Juergen Rech⁷, Ruvie Martin⁸, Gregory Ligozio⁸, Ken Abrams⁸ and Luminita Pricop⁹, ¹Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴University of Queensland, Brisbane, Australia, ⁵Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ⁶Rheumatology, CHU Montpellier, Montpellier University, Montpellier, France, ⁷Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab provided rapid, significant and sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) in multiple Phase 3 studies.1-4 Herein, we report…
Abstract Number: 635 • ACR/ARHP Annual Meeting 2017
Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Dongze Wu, Jiang Yue and Lai-Shan Tam, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: According to EULAR recommendations, in patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, biologic DMARDs targeting IL-12/23,…
Abstract Number: 1562 • ACR/ARHP Annual Meeting 2017
Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Numa Simons¹, Yannick Degboé¹, Thomas Barnetche², Alain Cantagrel¹, Adeline Ruyssen-Witrand¹ and Arnaud Constantin¹, ¹Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France
Background/Purpose: We are currently witnessing a diversification of the available biotherapies (bDMARDs) for psoriatic arthritis (PsA), with the arrival of new classes of medication. Those…
Abstract Number: 2848 • ACR/ARHP Annual Meeting 2015
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…